Regulating Homeopathic Drugs: Pragmatic Solutions for the Food and Drug Administration by Gelfond, Rebecca J.
 
Regulating Homeopathic Drugs: Pragmatic Solutions for the Food
and Drug Administration
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Regulating Homeopathic Drugs: Pragmatic Solutions for the Food
and Drug Administration (1999 Third Year Paper)
Accessed February 19, 2015 9:34:29 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:8846788
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAARegulating Homeopathic Drugs: Pragmatic Solutions
for the Food and Drug Administration
Rebecca Gelfond
Food and Drug Law
Professor Hutt
February 8, 1999
Neither the formulas of the past nor the technology of the present proved to have any eect,
beyond, perhaps, a certain reassurance for user and receiver.
| Johannes de Ketham, Fasciculus Medicinae, 14951
Homeopathy is a theory and practice of medicine that purports to treat symptoms of diseases
with drugs that produce symptoms or reactions in the body similar to a given disease in a
healthy person.2 The foundation of homeopathy is the notion that \like treats like" (similia
similibus curentur). As such, the word \homeopathy" itself is derived from the Greek words
homoios, which means similar, and pathos, which means either suering or disease.3
Although homeopathic drugs in the United States have been used by a limited number of patients and
prescribed on a similarly small scale by physicians, pharmacists, and manufacturers, there has been a recent
dramatic growth in their use.4 According to the American Homeopathic Pharmaceutical Association, \[t]he
1995 retail sales of homeopathic medicines in the United States were estimated at $201 million and growing
2Distinct from homeopathic medicine, \allopathic medicine" is dened as a \treatment whose action is directly opposed to
or incompatible with the eects of the disease." Jeremy Swayne, Homeopathic Method: Implications for Clinical Practice and
Medical Science 207 (1998). Unlike homeopathy, most conventional treatments are considered to be allopathic.
3See Compliance Policy Guide x 400.400, Conditions Under Which Homeopathic Drugs May be Marketed (1995), reprinted
in <http://www.fda.gov> [hereinafter Compliance Policy Guide]; Isadora Stehlin, Homeopathy: Real Medicine or Empty
Promises?, FDA Consumer Magazine, December 1996, reprinted in <http://www.fda.gov>. See also Conditions Under Which
Homeopathic Drugs May be Marketed; Availability of Compliance Policy Guide, 53 Fed. Reg. 21728 (1988) (notice).
4See Paolo Bellavite & Andrea Signorini, Homeopathy: A Frontier in Medical Science ix (1995).
1at a rate of 20 percent a year, [and] the number of homeopathic practitioners in the United States has
increased from fewer than 200 in the 1970s to approximately 3,000 in 1996."5 Additionally, a recent study
concluded that the use of alternative medicine in the United States has \increased substantially" from 1990
to 1997.6
Despite the growth of both the use of homeopathic drugs and the homeopathic drug industry, the Food
and Drug Administration (FDA) has not altered its regulatory scheme for homeopathic drugs.7 As a result,
homeopathic drugs are allowed on the market without any evidence that they are either safe or eective.
The growing use of homeopathic drugs suggests that the FDA should reconsider its stance on homeopathic
drugs so as to ensure consumer safety but yet preserve consumer choice.8
5Stehlin, supra note 3. Another source indicated that the homeopathic drug industry was at $250 million in the 1990s and
growing at a rate of 20 to 25 percent. See Dana Ullman, The Consumer's Guide to Homeopathy 34 (1995). Moreover, 75%
of chain drugstores are selling some homeopathic drugs as of 1994. See id.
6David M. Eisenberg, Roger B. Davis, Susan L. Ettner, Scott Appel, Sonja Wilkey, Maria Van Rompay & Ronald C. Kessler,
Trends in Alternative Medicine Use in the United States, 1990-1997, 280 JAMA 1569, 1572, 1574 (1998) (reporting that the
percentage of people who used a homeopathic drug within a year increased from 0.7% in 1990 to 3.4% in 1997)[hereinafter
Trends in Alternative Medicine].
7However, the National Institutes of Health (NIH) has taken action to study alternative medicine in the United States. The
NIH established the Alternative Medicine Program Advisory Council so that it may advise NIH \regarding the evaluation of
alternative medical treatment modalities, including acupuncture and Oriental medicine, homeopathic medicine, and physical
manipulation therapies." National Institutes of Health, Notice of Establishment, 58 Fed. Reg. 65727 (1993) (notice). Since
its creation, Congress has changed its name to the National Center of Complementary and Alternative Medicine and increased
its budget to $50 million from its previous $20 million. See Charles Marwick, Alterations are Ahead at the OAM, 280 JAMA
1553, 1553 (1998).
8The FDA confronts similar diculties with respect to the growing using of herbal remedies. This piece focuses only on
homeopathic drugs, which are distinct from herbal remedies. For discussions on possible approaches that the FDA could take
with respect to herbal remedies, see Edgard R. Cataxinos, Regulation of Herbal Medications in the United States: Germany
Provides a Model for Reform, 1995 Utah L. Rev. 561 (1995) and Scott Martin, Note, Unlabelled \Drugs" as U.S. Health
Policy: The Case for Allowing Health Claims on Medicinal Herb Labels; Canada Provides a Model For Reform, 9 Ariz. J.
Int'l & Comp. L. 545 (1992).
2I. The History and Practice of Homeopathy9
A.
The Rise of Homeopathy and its General Practice
Although homeopathy's principles date back as far as several thousands of years,10 the present
practice of homeopathy follows the teachings of Samuel Hahnemann, a German physician who
practiced in the late 1700s and 1800s.11 Homeopathy developed in response to the use of
harmful bleeding techniques and other dangerous techniques practiced by conventional practi-
tioners over two centuries ago.12 In the early 1700s bloodletting was one of the most common
treatments for many dierent diseases, with some physicians removing as much as four-fths
of a patient's blood.13 In addition to bleeding, physicians employed other equally ineective
and yet highly dangerous methods. Such methods included blistering a patient, which involved
the application of very hot substances that were thought \to draw out infections," inducing
vomiting, which involved the use of dangerous chemicals, and purging of ones bowels using
toxic chemicals.14
In contrast to these drastic and highly dangerous practices, homeopathy strove to treat con-
ditions with very mild medications that were highly diluted.15 In developing homeopathic
drugs to replace these methods, Samuel Hahnemann developed a theory of treatment that
was centered around three main principles: \the law of similars, the minimum dose, and the
single remedy."16
9For a brief and accessible background and explanation of homeopathy, visit the webpage of Healthy Net at
<http://www.healthy.net>.
10See Angela A. Mickelson, William H. Dailey, Soram Singh Khalsa & Mary L. Kedak, Managed Care Potpourri IV: Where
Oh Where is Complementary/Alternative Case, 19 Whittier L. Rev. 119, 122 (1997) [hereinafter Managed Care].
11See Homeopathy and `Homeopathy,' Answers on FDA WebPage, at 1, September 15, 1988, cited in <http://www.fda.gov>
[hereinafter Homeopathy and `Homeopathy'].
12See id.
13See Stehlin, supra note 3.
14Id. One such drug used to cleanse the bowels involved large doses of mercury and calomel. See id. This same concoction
also caused hair loss, loosened teeth, and induced several other negative symptoms associated with acute mercury poisoning.
See id.
15See Homeopathy and `Homeopathy', supra note 11, at 1.
16Stehlin, supra note 3.
3Hahnemann rst began using this homeopathic method after discovering that a large does of quinine (used
to treat malaria) induced in his healthy body the same symptoms of malaria itself.17 From this discovery,
he began to test other drugs in smaller dosages to determine how they aected the symptoms of the body.18
Through testing on himself, his family, and his friends, Hahnemann made several \provings"|experiments
that tested the ecacy of various dosages of various herbs, minerals, and other substances.19 These provings,
which were conducted on humans and resulted in symptom proles, were used to verify the ecacy of a
particular homeopathic drug.
Because of the strong adverse eects that these substances had on patients during these provings, Hahnemann
began experimenting with smaller and smaller doses.20 He believed that the smaller the dose, the stronger the
drug's strength and eectiveness became.21 Hahnemann, applying the law of innitesimals, would repeatedly
dilute the active ingredient by factors of ten.22 Each of these dilutions were followed by vigorous shaking
{ this was believed to \release[] the healing energy of the remedy."23 Although Hahnemann was aware of
the fact that repetitive dilutions of the active ingredient by factors of ten would most likely create dosages
in which not even a single molecule of the active ingredient existed, he still believed that \a spirit-like
essence could remain that could help stimulate the body."24 Homeopaths rely on the existence of the active
ingredients in very minute quantities despite the fact that even using current technology, it is unlikely that a
chemical analysis of a homeopathic drug would yield enough information to identify its active ingredient.25
Even more telling, Avagadro's number (6.023 x 1023) sets an experimentally proven limit on the amount of
dilution of an active ingredients that will result in a solution that contains any of the active ingredient.26 If
17See id.
18See id.
19See id.
20See id.
21See id.
22See id.
23Mahlon W. Wagner, Is Homeopathy `New Science' or `New Age'?, 1 Sci. Rev. Alternative Med. 7, 7 (1997).
24Homeopathy and `Homeopathy', supra note 11, at 1-2; see Stehlin, supra note 3.
25See Stehlin, supra note 3.
26See Stephen Barrett, \Alternative" Medicine: More Hype than Hope, in Alternative Medicine and Ethics 20-21 (James M.
4the dilution exceeds 24X, \[p]roponents [of homeopathy] acknowledge that there is virtually no chance that
even one original molecule would remain."27
Presently, prescription homeopathic drugs are still produced by repeatedly diluting the active ingredient by
a factor of ten, where ten is usually denoted by \X," the Roman numeral for ten.28 For example, a 9X
preparation has been diluted by a factor of ten, separately nine times so that the nal solution contains only
one part per billion of the active ingredient.29
Finally, homeopathic treatments are considered to be patient specic rather than merely disease specic. In
other words, homeopathic physicians attempt to give each of their patients a single remedy that is designed
to treat all of the patient's symptoms rather than providing the patient with independent remedies for
each symptom.30 By treating the patient as a whole, the homeopathic physician believes that she is able
to treat together both the mental and the physical symptoms that the patient is experiencing.31 This
holistic treatment attempts to focus not merely on addressing the patient's symptoms alone, but also on the
patient as a whole including consideration of the patient's genetic history, family history, and body type.32
Consequently, homeopathy results in a more individualized treatment.33
Humber & Robert F. Almeder, eds., 1998).
27Id. at 21.
28Homeopathy and `Homeopathy', supra note 11, at 1-2.
29Id.
30See Stehlin, supra note 3.
31See id.
32See id.
33See id.
5B. The Fall of Homeopathy
Homeopathy gained support in America following the studies of Hahnemann, but at the turn of the twentieth
century, homeopathy began to fall into disrepute. This was a result of three main factors. First, the
publication of the Flexner Report of 1910 attacked the validity of several schools of alternative medicine
including schools of homeopathy. \Compiled by Abraham Flexner... the report... examined the then-
existing medical schools in the United States and gave low grades to most of the schools which did not
practice or teach allopathic medicine.34 Many folded as a result."35 Consequently, most of the homeopathic
schools fell into disrepute, leaving allopathic medicine as the dominant school of medicine.36
Second, the increasing power of conventional medicine allowed it to act as an institution which ultimately
turned against alternative forms of medicine with which it was in competition.37 Eorts were taken to
undermine the practice of homeopathy including \`purg[ing]' homeopaths from their ranks, including expul-
sion from medical societies, lawsuits, attacks in the medical literature, and attempts to turn public opinion
against homeopathy."38
Finally, the rise of scientic medicine allowed conventional physicians to systematize their treatment and
diagnosis of their patients.39 This systemization of conventional medicine strengthened its power to unite
against alternative forms of medicine. The paradigm of conventional, or orthodox, medicine will be discussed
below in Part IV.A.4.(a).
34For a denition of \allopathic medicine," see supra note 2.
35Managed Care, supra note 10, at 122. See generally Naomi Rogers, An Alternative Path (1998) (providing a detailed
history of Hahnemann Medical College).
36See Managed Care, supra note 10, at 122.
37Michael A. Cohen, A Fixed Star in Health Care Reform: The Emerging Paradigm of Holistic Healing, 27 Ariz. St. L.J.
79, 126 (1995).
38Id. at 124.
39Id. at 125.
6II. The Ecacy of Homeopathy
There is both empirical and clinical evidence that suggests that homeopathy is valid. From an empirical
standpoint, the fact that homeopathy has survived through centuries of use and has spread widely across
the globe strongly suggests that it is eective.40 Furthermore, long-term use of homeopathic drugs over the
centuries has subjected them to a ltering process that attempts to weed out those drugs that either are
found to be unsafe or ineective.41 From a clinical (or what is often thought as a more scientic) perspective,
although many of the studies that have been conducted in order to show the ecacy of homeopathic drugs
were conducted with poor, unscientic methodology, there are a signicant number of valid studies that
suggest that homeopathic drugs may be eective.42 For examples, two independent meta-analyses have con-
cluded that homeopathic treatment is independent of any placebo eect.43 Although these studies indicate
that further research is necessary, they do show promise that homeopathy might actually be an eective
remedy. One study commented similarly: \The results of our meta-analysis are not compatible with the
hypothesis that the clinical eects of homeopathy are completely due to placebo. But there is insucient
evidence from these studies that any single type of homeopathic treatment is clearly eective in any one
clinical condition."44
While there are some hopeful reports regarding the ecacy of homeopathy,45 there is still a need for signi-
40See Bellavite & Signorini, supra note 4, at 38.
41See id. at 38-39.
42See id. at 42.
43See Klaus Linde, Nicola Clausius, Gilbert Ramirez, Dieter Melchart, Florian Eitel, Larry V. Hedges & Wayne B. Jonas,
Are the Clinical Eects of Homeopathy Placebo Eects? A Meta-analysis of Placebo-controlled Trials, 350 The Lancet 834,
834 (1997); David Reilly, Morag A. Taylor, Neil G. M. Beattie, Jim H. Campbell, Charles McSharry, Tom C. Aitchison, Roger
Carter & Robin D. Stevenson, Is Evidence for Homeopathy Reproducible?, 344 The Lancet 1601, 1601 (1994).
44Linde, supra note 43, at 839.
45See generally Bellavite & Signorini, supra note 4 (providing an overview of both experimental studies and theoretical
foundations of homeopathy); Fundamental Research in Ultra High Dilution and Homeopathy (Jurgen Schulte & P.
Christian Endler, eds., 1998) (examining various high dilution studies as well as other support of homeopathy); Signals and
Images: Selected Papers (Madeleine Bastide, ed., 1997) (providing a collection of technical papers that examine the ecacy
of high dilution treatments on various biological systems); Ultra High Dilution: Physiology and Physics (P.C. Endler &
7cantly more scientic evidence to support both its eectiveness and its safety. Even though there is empirical
and some clinical evidence that individual homeopathic drugs may be safe and eective, these facts cannot
adequately defend both the safety and eectiveness of homeopathic drugs in absence of studies that clinically
prove their eectiveness in individual clinical conditions.
Furthermore, the present studies cannot demonstrate the eectiveness of high-dilution drugs, which is a key
principle of homeopathy. The journal Nature published an article, commonly known as the \Benveniste
paper," which suggested that high-dilution drugs were in fact ecacious.46 The study claimed that solutions
of antibodies could be greatly diluted and yet still create a reaction in a certain type of white blood cell
with antibodies of the immunoglobulin E (IgE) type on its surface.47 This claim supports the homeopathic
theory that despite the very high dilution of the active ingredients, the solution remains eective. However,
additional studies led to evidence that Benveniste's study was awed.48 The follow-up report found that
Benveniste's study was both biased and poorly conducted. A supplier of homeopathic drugs paid the salaries
of two of the co-authors.49 Furthermore, the experiment was described as being inexact and not fully
investigated.50 One group of commentators reected on the ramications of the Benveniste paper: \This
incident shows why the hesitation of scientists to accept dramatically new ideas without adequate review
represents reasonable caution rather than conservative intransigence."51
J. Schulte, eds., 1994) (providing a collection of technical papers that examine the ecacy of high dilution treatments).
46E. Davenas, F. Beauvais, J. Amara, M. Oberbaum, B. Robinzon. A. Miadonna, A. Tedeschi, B. Pomeranz, P. Fortner,
P. Belon, J. Sainte-Laudy, B Poitevin & J. Benveniste, Human Basophil Degranulation Triggered by Very Dilute Antiserum
Against IgE, 333 Nature 816 (1988); see also Robert Pool, Unbelievable Results Spark a Controversy, 241 Science 407, 407
(1988) (describing the controversy surrounding the Benveniste paper).
47See Pool, supra note 46, at 407.
48John Maddox, James Randi & Walter W. Stewart, \High-dilution" Experiments a Delusion, 334 Nature 287 (1988).
49See id. at 287.
50See id. at 289-90.
51Bert Black, Francisco J. Ayala & Carol Saran-Brinks, Science and the Law in the Wake of Daubert: A New Search for
Scientic Knowledge, 72 Tex. L. Rev. 715, 779 (1994).
8Additionally, even when homeopathic drugs appear to be ecacious in some cases, these results can generally
be attributed to several other alternative causes. First, in the absence of more thorough studies, there is no
way of knowing whether the homeopathic drug caused the recovery or if, in fact, a placebo eect caused the
patient's recovery.52 \Many who don't believe in homeopathy's eectiveness say any successful treatments
are due to the placebo eect, or, in other words, positive thinking."53 This is not to say that there is always
a placebo eect,54 but there are specic cases in which it has been found. For example, a study that tested
the ecacy of Rhus toxicodendron, extracts of poison oak, which homeopaths use to treat osteoarthritis,
found that the \eects of Rhus tox. 6X and placebo did not dier signicantly."55
Second, there is no way of knowing whether or not the patient's symptoms were relieved due to natural
changes in symptoms through the course of a disease or even whether remission was induced by the treatment
or had natural causes.56 Many conditions, given time, will often go away on their own. This critique is
particularly applicable to the use of over-the-counter (OTC) homeopathic drugs because of their application
to only self-limiting conditions.
Third, in absence of a strict regulation of homeopathic drugs, it cannot be known whether the homeopathic
drugs alone caused the suppression of the symptoms or if, in fact, the homeopathic drug contained an eective
does of another active ingredient that actually cured the disease.57
Fourth, because it is dicult to measure the actual dosage of the active ingredient in the drug, there is no
52William Jarvis, M.D., Consumer Forum, Consumer Magazine, April 1997, reprinted in <http://www.fda.gov>.
53Stehlin, supra note 3. However, the placebo eect cannot be the entire reason that homeopathic drugs are found to be
eective because they have been found eective in both infants and animals, for whom the placebo eect is inapplicable.
Furthermore, many patients who are treated with homeopathic drugs for chronic illnesses experience a \so-called healing crisis
or homeopathic aggravation" in which the symptoms are increased. See Bellavite & Signorini, supra note 4, at 40. This
eect is inconsistent with the placebo eect. See id.
54See generally Linde, supra note 43; Reilly, supra note 43.
55Michael Shipley, Hedley Berry, Gill Broster, Michael Jenkins, Anne Clover & Ivan Williams, Controlled Trial of Homeopathic
Treatment of Osteoarthritis, The Lancet, January 15, 1983, at 97.
56See Jarvis, supra note 52; Wagner, supra note 23, at 9.
57See Jarvis, supra note 52.
9way of telling if a dose of the drug actually contained an eective dosage of the active ingredient that could
have actually caused the decline in the symptoms.58
Fifth, patients who seek homeopathic treatment, have often found that traditional Western practices were
ineective, and hence see homeopathic drugs as remedies of a last resort. Under this mindset, users of
homeopathic drugs might claim that the homeopathic medication is working despite the fact that they are
still experiencing the symptoms of their ailment.59
Sixth, representations that homeopathic drugs do in fact work eectively can be the source of fraudulent
and inaccurate studies and reports.60 For example, a clinical experiment purported that some homeopathic
treatments might be useful in treating acute diarrhea in children; these results were published in the May
1994 issue of Pediatrics. However, in November 1995, another article appeared in Pediatrics that showed
that the previous study was awed in several respects.61 Although there was probably not fraudulent intent
here, this example goes to support the fact that many studies that seemingly support the eectiveness of
homeopathic drugs are awed. \Although Pediatrics is published by the American Academy of Pediatrics,
Jacobs' study and several others published in such journals as The Lancet and the British Medical Journal
are considered `scanty at best' by the academy."62
Ultimately, although there is some scientic evidence that supports the eectiveness of homeopathy, there
are several other factors and studies that suggest that homeopathy is ineective. As a result, in order to
determine whether homeopathy is in fact eective, much additional experimentation, using more rigorous
methodologies is necessary.
58See id.
59See id.
60See id.
61See Stehlin, supra note 3.
62Id.
10III. Homeopathy and its Treatment in Food and Drug Law
A. The History of Homeopathy in Food and Drug Law
Despite the fact that homeopathy had fallen into disrepute at the turn of the twentieth century as allo-
pathic medicine became the dominant medical practice in the United States, homeopathy was still given
an important status in the Federal Food, Drug, and Cosmetic Act of 1938 (1938 Act). As both the chief
sponsor of the Federal Food, Drug, and Cosmetic Act of 1938 and also as a homeopathic physician, Senator
Royal Copeland of New York amended the Food and Drugs Act of 1906 by dening \drug" to include those
homeopathic drugs that are listed in the Homeopathic Pharmacopoeia of the United States (HPUS).63 The
HPUS is a \compilation of standards for source, composition, and preparation of homeopathic drugs,"64
which the 1938 Act also recognized as an ocial compendium.65 The 1962 amendments to the 1938 Act left
this inclusion of homeopathic drugs within the statutory denition of \drug."66
63See Compliance Policy Guide, supra note 3; Homeopathy and `Homeopathy', supra note 11, at 2; Stehlin, supra note 3.
Specically, the Federal Food, Drug, and Cosmetic Act of 1938 denes \drug" as:
(A) articles recognized in the ocial United States Pharmacopoeia, ocial Homeopathic Pharmacopoeia of the United
States, or ocial National Formulary, or any supplement to any of them; and (B) articles intended for use in the diagnosis,
cure, mitigation, treatment, or prevention of disease in man or other animals; and (C) articles (other than food) intended to
aect the structure or any function of the body of man or other animals; and (D) articles intended for use as a component
of any article specied in (A), (B), or (C) of this paragraph.... A food, dietary ingredient, or dietary supplement for which a
truthful and not misleading statement is made in accordance with section 343(r)(6) of this title is not a drug under clause (C)
solely because the label or the labeling contains such a statement.
Federal Food, Drug, and Cosmetic Act, 21 U.S.C. x 321(g)(1) (1998). See also United States v. Writers & Research, Inc.,
113 F.3d 8, 11 (2nd Cir. 1997) (nding that a homeopathic drug was subject to the requirements of the Act); Meserey v.
United States, 447 F. Supp. 548, 552-53 (D. Nev. 1977) (conrming that homeopathic remedies, if listed in the HPUS, should
be treated as drugs under the Act). It should be noted, however, that the FDA ultimately determines how homeopathic drugs
will be regulated under the Act.
64Compliance Policy Guide, supra note 3; see Homeopathy and `Homeopathy', supra note 11, at 2; Stehlin, supra note 3.
65See 21 U.S.C. x 321(j). \The term `ocial compendium' means the ocial United States Pharmacopoeia, ocial Homeo-
pathic Pharmacopoeia of the United States, ocial National Formulary, or any supplement to any of them." Id.
66See Homeopathy and `Homeopathy', supra note 11, at 2.
11B. The FDA's Current Stance on Homeopathic Drugs
The FDA treats homeopathic drugs, both prescription and OTC, quite dierently than conventional or
allopathic drugs. Perhaps most importantly, unlike conventional drugs, homeopathic drugs are not required
to submit to pre-market approval, which involves ling for a new drug application (NDA) in order to market
the drug. In fact, no homeopathic drug has successfully applied for an NDA. Because of this key exclusion,
homeopathic drugs are marketed without having been proven to be safe or eective. Furthermore, unlike
other OTC drugs, which are either required to submit to OTC Review or to apply for an NDA,67 OTC
homeopathic drugs are not required by the FDA to be tested for safety or eectiveness.68 Arguably, the 1938
Act does require that homeopathic drugs meet the standards set forth by the Homeopathic Pharmacopoeia
of the United States. However, this does not ensure their safety and eectiveness under the FDA's standards:
a \product's compliance with requirements of the HPUS... does not establish that it has been shown by
appropriate means to be safe, eective, and not misbranded for its intended use."69
Other, perhaps less signicant, dierences between the way in which conventional and homeopathic drugs
are regulated also exist. First, homeopathic drugs that are ingested in solid, oral dosages are required to be
imprinted so that the imprint both identies the manufacturer of the drug and indicates that the drug is
homeopathic.70 This requirement is less stringent than that which is required of other conventional drugs,
67See infra Part IV.A.
68Procedures for Classication of Over-the-Counter Drugs, 37 Fed. Reg. 9464, 9466 (1972) (to be codied at 21 C.F.R. pt.
130).
69Compliance Policy Guide, supra note 3. The Act also species the treatment of combined homeopathic and non-homeopathic
drugs. The statute states:
Whenever a drug is recognized in both the United States Pharmacopoeia and the Homeopathic Pharmacopoeia of the United
States it shall be subject to the requirements of the United States Pharmacopoeia unless it is labeled and oered for sale as a
homeopathic drug, in which case it shall be subject to the provisions of the Homeopathic Pharmacopoeia of the United States
and not to those of the United States Pharmacopoeia.
21 U.S.C. x 351 (1998).
70See Imprinting of Solid Oral Dosage For Drug Products for Human Use, 58 Fed. Reg. 47,948, 47,949, 47,951 (1993) (to be
12which are also required to imprint on solid, oral dosages the active ingredient and strength of the dosage,
rather than simply the manufacturer.71 Homeopathic drugs were exempted from this requirement because
the FDA concluded that the costs of this requirement would outweigh any incremental safety benets that
would result, especially given the fact that homeopathic drugs are held to the standards of the HPUS.72
Second, homeopathic drugs in liquid form are held to a lower standard than are conventional drugs with
respect to regulations on alcohol content.73 Conventional OTC drugs intended for adult consumption are not
allowed to be composed of more than ten percent of alcohol.74 However, the FDA has exempted homeopathic
drugs from this restriction.75 The FDA succumbed to comments which suggested that the removal of alcohol
as a common solution for the homeopathic treatments would undermine the integrity of homeopathic drugs
and require completely new analysis of the ecacy of the drugs, a very costly requirement.
Despite the fact that homeopathic drugs are treated in a substantially dierent manner than conventional
drugs, the FDA has placed several restrictions on the marketing of homeopathic drugs. The essence of the
FDA's stance on the marketing of homeopathic drugs can be found its Compliance Policy Guide (CPG),
\Conditions Under Which Homeopathic Drugs May be Marketed."76
The scope of the FDA's denition of homeopathy is expressed in this CPG: the FDA denes homeopathy as
\[t]he practice of treating the syndromes and conditions which constitute disease with remedies that have
produced similar syndromes and conditions in healthy subjects," it denes a homeopathic drug as \[a]ny
codied at 21 C.F.R. pts. 206, 207, 314, 330); Stehlin, supra note 3.
71See Imprinting of Solid Oral Dosage For Drug Products for Human Use, 58 Fed. Reg. at 47,949; Stehlin, supra note 3.
72See Imprinting of Solid Oral Dosage For Drug Products for Human Use, 58 Fed. Reg. at 47,957, 47,950.
73See Stehlin, supra note 3.
74See Over-the-Counter Drug Products Intended for Oral Ingestion that Contain Alcohol, 60 Fed. Reg. 13,590, 13,590 (1995)
(to be codied at 21 C.F.R. pt. 328); Stehlin, supra note 3.
75See Over-the-Counter Drug Products Intended for Oral Ingestion that Contain Alcohol, 60 Fed. Reg. at 13,593; Stehlin,
supra note 3.
76Compliance Policy Guide, supra note 3.
13drug labeled as being homeopathic which is listed in the Homeopathic Pharmacopoeia of the United States
(HPUS), an addendum to it, or its supplements."77 Thus, any homeopathic drug is required to be labeled as
such. Furthermore, those drugs that contain homeopathic and non-homeopathic ingredients are considered
to be non-homeopathic drugs.78
Although the CPG on homeopathic drugs does not require any sort of pre-market approval, it does purport
to subject homeopathic drugs to current good manufacturing practices, hold homeopathic drugs to several
labeling requirements, monitor OTC versus prescription use of homeopathic drugs, and protect against fraud.
First, the FDA does not allow health fraud with respect to homeopathic drugs. The CPG denes \health
fraud" as:
The deceptive promotion, advertisement, distribution or sale of articles, intended for human
or animal use, that are represented as being eective to diagnose, prevent, cure, treat, or
mitigate disease (or other conditions), or provide a benecial eect on health, but which
have not been scientically proven safe and eective for such purposes. Such practices may
be deliberate, or done without adequate knowledge or understanding of the article.79
Although this suggests that homeopathic drugs should be safe and eective, in fact, because they
are not held to the requirement of pre-market approval, there is little way for the FDA to know if
claims of many homeopathic drugs are in fact inaccurate because the drug is ineective or unsafe.
Second, the FDA limits the marketing of nonprescription homeopathic drugs to those that treat only \self-
limiting" conditions that the average consumer can recognize and diagnose.80 As a result, homeopathic drugs
that claim to reduce serious diseases that require actual diagnoses by a licensed physician, including AIDS
and cancer, are required to be marketed as prescription only drugs.81 Otherwise, the distinction between
prescription versus OTC status is determined according to section 353(b), as with conventional drugs.82
77Id.
78See id.
80See id.; Homeopathy and `Homeopathy', supra note 11, at 2-3; Stehlin, supra note 3.
81See Compliance Policy Guide, supra note 3; Homeopathy and `Homeopathy', supra note 11, at 2-3; Stehlin, supra note 3.
82See Compliance Policy Guide, supra note 3.;
14Under section 353(b), habit forming drugs and a drug, which \because of its toxicity or other potentiality
for harmful eect, or the method of its use, or the collateral measures necessary to its use, is not safe for
use except under the supervision of a practitioner licensed by law to administer such drug," are considered
prescription drugs.83
Third, the FDA requires that homeopathic drugs be properly labeled. Homeopathic drugs are required to
comply with the labeling provisions of 21 U.S.C. x 352.84 As part of this requirement, a \drug or device
shall be deemed to be misbranded... [i]f its labeling is false or misleading in any particular."85 Furthermore,
section 352 of the Act requires that the name and place of business of the manufacturer, packer, or distributor
be placed on the package.86 Homeopathic drugs for retail sale must also bear adequate directions for use
that can be interpreted by the average lay person as required under section 352(f), their ingredients as well
as their dilutions (which expresses how many parts per power of ten of the active ingredients that the drug
actually contains), at least one major indication for the drug, the drug's established name in accordance with
section 352(e), and any applicable warnings.87 Additionally, \[d]ocumentation must be provided to support
that those products or ingredients which are not recognized ocially in the HPUS, an addendum to it, or
its supplements are generally recognized as homeopathic products or ingredients."88
Prescription drugs should comply with the General Labeling Provisions required for nonprescription drugs
8321 U.S.C. x 353(b)(1) (1998).
84See Compliance Policy Guide, supra note 3.
8521 U.S.C. x 352(a) (1998).
86See id.; 21 U.S.C. x 352(b) (1998).
87See Compliance Policy Guide, supra note 3. Section 352(f) indicates in pertinent part:
Unless its labeling bears (1) adequate directions for use; and (2) such adequate warnings against use in those pathological
conditions or by children where its use may be dangerous to health, or against unsafe dosage or methods or duration of
administration or application, in such manner and form, as are necessary for the protection of users, except that where any
requirement of clause (1) of this paragraph, as applied to any drug or device, is not necessary for the protection of the public
health, the Secretary shall promulgate regulations exempting such drug or devise from such requirement.
21 U.S.C. x 352(f) (1998). An exemption from adequate directions for use, as described in x 353(b)(2) is only allowed for
prescription drugs. See Compliance Policy Guide, supra note 3.
88Compliance Policy Guide, supra note 3.
15as well as some additional requirements. As required by section 353(b)(4), all \[p]rescription homeopathic
drugs must be labeled, `Caution: Federal law prohibits dispensing without prescription."'89 Prescription
homeopathic drugs shall also include a statement of identity, declaration of net quantity of contents and
statement of dosage, and a physician package insert.90
Fourth, the FDA requires that homeopathic drugs generally be manufactured in conformance with current
good manufacturing practice.91 However, there are two exemptions to this requirement.92 First, homeo-
pathic drugs need not have expiration dating.93 Second, the FDA proposed an amendment that exempted
homeopathic drug products from the requirement for laboratory determination of identity and strength of
each active ingredient prior to the release and distribution of the drug on the market.94 Until there is a nal
ruling on this proposed amendment, the FDA has a policy not to enforce this regulation against homeopathic
drugs.95
C. Why Does the FDA Treat Homeopathic Drugs Dierently?
There are several often-cited reasons for applying less strict regulations to homeopathic drugs than are
applied to allopathic or conventional drugs. First, because homeopathic drugs, by design, contain such
89Homeopathy and `Homeopathy', supra note 11, at 2-3; see Compliance Policy Guide, supra note 3.
90See Compliance Policy Guide, supra note 3.
91See id.
92See id.
93See id.; 21 C.F.R. x 211.165 (1998).
94See Compliance Policy Guide, supra note 3; Current Good Manufacturing Practice in Manufacture Processing, Packing, or
Holding; Proposed Exemption from Active Ingredient Identity and Strength Testing for Homeopathic Drug Products, 48 Fed.
Reg. 14,003 (1983) (to be codied at 21 C.F.R. pt. 211) (proposed April 1, 1983). The FDA argued that the minute benets
of requiring this testing of homeopathic drugs were outweighed signicantly by the costs to the manufacturers of homeopathic
drugs. See id. at 14,004. Also, the FDA felt that the restrictions of the Homeopathic Pharmacopoeia of the United States
would suciently solve any risks that were caused by the exemption. See id.
95See id.
16innitesimal amounts of any given active ingredient, it is dicult to imagine that even active ingredients
that could be toxic in certain dosages can ever have a toxic eect in a mixture in which it is only one part
per million or even less.96 As such, from a toxicity, poison-control standpoint, safety regulations that are
applicable to conventional drugs should not necessarily be applied to homeopathic drugs.97
Second, the FDA has considered homeopathic drugs to be distinct from conventional drugs and has hence
traditionally separated its treatment of them as far as regulating them. New exemptions that the FDA has
granted to homeopathic drugs are simply consistent with the FDA's longstanding approach of segregating
regulation of homeopathic drugs from conventional medications.98
Third, one must remember that the FDA does in fact have limited time and resources. The relative costs
and benets of regulating homeopathic drugs rather than expending energy in other areas of regulation must
always be evaluated when considering new methods of regulating homeopathic drugs.
IV. Possible Alternative Approaches to the FDA's Treatment of Homeopathic Drugs
Despite the foregoing reasons that are often used to justify the continuation of the FDA's stance of inaction
toward homeopathic drugs, the growing popularity and use of homeopathy suggests that the FDA should re-
consider its policy of inaction toward homeopathic drugs. The FDA has a spectrum of alternative approaches
to the regulation of homeopathic drugs.
96See Stehlin, supra note 3. This reasoning was espoused by Edward Miracco, a consumer safety ocer at the FDA's Center
for Drug Evaluation and Research.
97See id. (quoting Edward Miracco, a consumer safety ocer at the FDA's Center for Drug Evaluation and Research). But
see infra Part IV.A.3.(a).
98See Stehlin, supra note 3.
17A.
Treating Homeopathic Drugs as Conventional Drugs
A commonly mentioned alternate treatment of homeopathic drugs is to require that they go through the
same approval process as do conventional drugs.99 Under this requirement, homeopathic drugs would have
to be tested for both safety and eectiveness. This would require all homeopathic drugs100 either to le an
NDA or to submit to the OTC Review Process. As will be elaborated below, despite its advantages in terms
of proving safety and eectiveness, this alternative will have devastating results on the homeopathic drug
industry.
1. The Pre-market Approval Process
Conventional drugs are required to go through a rigorous, costly, and time-consuming testing process. To
understand the consequences of such an approach it is important to address the process that pre-market
approval of conventional drugs presently entails.
Currently, the FDA places conventional drugs in three dierent categories: (1) new drugs, (2) drugs that are
generally recognized as safe (GRAS) and generally recognized as eective (GRAE), (3) and drugs that fall
under the grandfather clauses of the 1938 Act or the 1962 amendments.101
Under section 321(p)(1) of the Act, in order for a drug to be considered GRAS and GRAE, the manufac-
turer must show that the drug is \generally recognized, among experts qualied by scientic training and
experience to evaluate the safety and eectiveness of drugs, as safe and eective for use under the conditions
99This approach was advocated by Jarvis, supra note 52, and the National Council Against Health Fraud, NCAHF Position
Paper on Homeopathy, Feb. 1994, in <http://www.ncahf.org/pos-pap/homeop.html>.
100The FDA would still be unable to require pre-market approval of those homeopathic drugs that fall under the umbrella of
the grandfather clauses of the 1938 Act or the 1962 amendments to the Act. See infra IV.A.1.
101See 21 U.S.C. x 321(p)(1) (1998).
18prescribed, recommended, or suggested in the labeling thereof."102 Although one might argue that home-
opathic drug manufacturers could claim that their drugs are GRAS and GRAE, this will not excuse such
manufacturers from showing that their product is safe and eective. \FDA has taken the view that general
recognition of safety and ecacy on the part of qualied experts must be based on scientic evidence, rather
than personal experience or anecdotes,"103and this requirement has been upheld by the Supreme Court.104
As a result, it is unlikely that many homeopathic drugs will be able to withstand this requirement without
conducting new clinical trials and experiments because of the lack of scientic studies that prove the eec-
tiveness of many homeopathic drugs and, in particular, because of the inability to prove that any ecacy
that is found is not caused by the placebo eect or is consistent with no treatment intervention.
Unlike the GRAS and GRAE exception, it is possible that many homeopathic drugs might fall under the
umbrella of the Act's grandfather clauses. There are two independent grandfather clauses. First, section
201(p) of the 1938 Act indicated that the safety requirement of the Act would not apply to those drugs that
were marketed under the 1906 Act and for which the labeled representations were the same. This grandfa-
ther clause remained unchanged after the 1962 Amendments. The statute indicates that a drug is exempt
from showing safety and eectiveness if \at any time prior to the enactment of this chapter it was subject to
the Food and Drugs Act of June 30, 1906, as amended, and if at such time its labeling contained the same
representations concerning the conditions of its use."105 The 1962 Amendments also created transitional
grandfather provisions in section 107(c) of the Amendments.106 The relevant parts of these provisions indi-
cate that in order to fall under the grandfather clause a drug (1) must have been in commercial distribution
prior to the passage of the Act on October 9, 1962; (2) must have not been a new drug under the 1938 Act;
102Id.
103Joseph A. Page, Federal Regulation of Tobacco Products and Products that Treat Tobacco Dependence: Are the Playing
Fields Level?, 53 Food & Drug L.J. 11, 17 (1998).
104See Weinberger v. Bentex Pharmaceuticals, Inc., 412 U.S. 645 (1973); Weinberger v. Hynson, Westcott & Dunning, Inc.,
412 U.S. 609 (1973), cited in Page, supra note 103, at 17.
10521 U.S.C. x 321(p)(1) (1998).
106These provisions are not codied in the statute.
19(3) must not have been covered under a new drug application as of the passage of the Act on October 9, 1962;
(4) and must have been intended solely for use under conditions prescribed, recommended, or suggested in
the labeling with respect to such drug as of October 9, 1962.107 Despite the breadth that these statutory
exceptions might suggest, the courts have interpreted these grandfather clauses narrowly:
[W]e construe the critical language of the Grandfather Clauses to exempt drugs not generally
recognized as eective if on the eective date of the Act the labeling contained the same
representations concerning its use, and thus conne the exemptions to drugs intended solely
for use under conditions prescribed on the eective date of the Act.108
It is unclear, under this interpretation of the grandfather clauses, whether a signicant number of home-
opathic drugs would in fact fall under the umbrella of the grandfather clauses. Unlike conventional drugs
of which few fall under the grandfather clause, it is possible that many more homeopathic drugs would
fall under this umbrella. For example, the Dictionary of Practical Materia Medica, which describes several
homeopathic drugs that are still used today, was available as early as 1900.109 However, although it is
true that many homeopathic drugs have been in use for centuries, it is unclear to what extent the label-
ing of these drugs and their indications of use have changed since 1962. In particular, it seems likely that
the labeling of OTC homeopathic drugs might have changed more recently than prescription homeopathic
drugs. Therefore, because most homeopathic drugs are sold OTC without a prescription,110 application of
the grandfather clauses might be limited. It should, however, be noted that, under the current grandfather
clauses, it is likely that many homeopathic drug manufacturers will claim to fall under the umbrella of the
grandfather clauses.
New drugs are dened as those drugs that neither fall under the grandfather clauses nor are recognized
107See Section 107(c)(4) of the 1962 amendments; Charles J. Walsh &Alissa Pyrich, Rationalizing the Regulation of Pre-
scription Drugs and Medical Devices: Perspectives on Private Certication and Tort Reform, 48 Rutgers L. Rev. 883, 898
(1996).
109John Henry Clarke, M.D., A Dictionary of Practical Materia Medica (1900).
110National Center for Homeopathy, Homeopathy: Natural Medicine for the 21st Century 4 (1993).
20as GRAS and GRAE.111 Because of the strict requirements for GRAS and GRAE, it seems reasonable to
consider most homeopathic drugs that do not fall under one of the grandfather clauses as new drugs. The
FDA requires that the FDA approve all new drugs before marketing them. This process of pre-market
approval involves three stages: \(1) Preclinical research aimed at the discovery and identication of drug
which is suciently promising to study in humans; (2) Clinical research to determine human ecacy and
side eects (IND, Phases I, II, III)[; and] (3) FDA evaluation and approval of a new drug application
(NDA)."112 After the initial animal testing in Stage 1, drug manufacturers le a \Claimed Exemption for an
Investigational New Drug" (IND), which the FDA has thirty days to review in order to determine whether
human testing should occur. Stage 2 then involves three independent phases:
[In Phase I] ...the clinical pharmacologist has the responsibility of administering the drug to a
human volunteer for the rst time.... in order to ascertain drug metabolism and excretion and also
to estimate the potential of the drug for producing adverse eects.... [Phase II is the] rst time [the
drug] is studied in patients with the disease which the drug is designed to treat.... The objective is
to determine whether the drug has the desired therapeutic eect, the dose range at which this eect
occurs, and whether any adverse eects observed will limit the drug's usefulness.... [In Phase III]
hundreds and even thousands of patients are investigated.... Usually masked, comparative studies
with placebo or a standard drug are carried out, and great care is taken to detect adverse reactions
and potential interaction of the new drug with other medications.113
After completion of Stage 2 and Stage 3 studies, the drug manufacturer les an NDA, which includes the
results of the previous studies. The FDA then has at least 180 days to review the application.
During the FDA's review process, the FDA makes the determination whether the new drug is both safe and
eective. Specically, section 355(d) of the Act requires the FDA to deny an application for a new drug if
the application does not \include adequate tests by all methods reasonably applicable to show whether or
not such drug is safe for use under the conditions prescribed, recommended, or suggested in the proposed
111See 21 U.S.C. x 321(p)(1) (1998).
112The Food and Drug Administration's Process for Approving New Drugs, Report of the Subcommittee on Science, Research
and Technology of the House Committee on Science and Technology, 96th Congress, 2nd Session (1980), in Peter Barton
Hutt & Richard A. Merrill, Food and Drug Law 514 (2nd ed. 1991) [hereinafter Process for Approving New Drugs].
21labeling thereof...." This determination was claried in a Senate Committee meeting:
The decisionmaking process can conveniently be regarded as a three-step operation....
Step 1. Determine the benet to be derived from the drug;
Step 2. Determine the risk; and
Step 3. Weigh the benet against the risk and decide whether it is in the public interest
to approve the drug for marketing or to withdraw approval if the product is already on the
market.114
Furthermore section 355(d) of the Act requires that the FDA deny a new drug application if it nds that
\there is a lack of substantial evidence that the drug will have the eect it purports or is represented to have
under the conditions of use prescribed, recommended, or suggested in the proposed labeling thereof...."115
The Act goes on to dene \substantial evidence" as:
evidence consisting of adequate and well-controlled investigations, including clinical investi-
gations, by experts qualied by scientic training and experience to evaluate the eectiveness
of the drug involved, on the basis of which it could fairly and responsibly be concluded by
such experts that the drug will have the eect it purports or is represented to have under
the conditions of use prescribed, recommended, or suggested in the labeling or proposed
labeling thereof.116
The FDA Modernization Act of 1997 has claried the standard of \substantial evidence" by allowing the
FDA, at its discretion, to consider a single well-controlled study to be a sucient showing of substantial
evidence of ecacy.117
2. The OTC Review Process
Until the amendments to the Federal Food, Drug, and Cosmetic Act in 1962, very few OTC drugs had
been approved by the FDA under the assumption that they were GRAS. However, the 1962 amendments
required that all drugs be found to be eective as well. This created a formidable task for the FDA because
11521 U.S.C. x 355(d) (1998) (emphasis added).
117Id.
22of the large number of OTC drugs (in the hundreds of thousands) that were already on the market. In
response, FDA began what came to be known as the OTC Review. The OTC Review involved a massive
eort to study the safety and eectiveness of the active ingredients of OTC drugs. As a key component
of this Review, FDA established \panels of qualied experts to evaluate the safety and eectiveness of
OTC drugs, to review OTC drug labeling, and to advise... on the promulgation of monographs establishing
conditions under which OTC drugs are generally recognized as safe and eective and not misbranded."118
This determination relied upon human experience during marketing, expert opinion, published studies, and
controlled clinical investigations.119 After the review process, the panel would categorize the drugs in either
one of three categories:
Category I: OTC drugs that are generally recognized as safe and eective and not mis-
branded;
Category II: OTC drugs that were not generally recognized as safe and eective and mis-
branded; and
Category III: OTC drugs for which the data was insucient.120
Category I drugs were left on the market; category II drugs were removed from the market; and Category
III drugs were left on the market until further studies were made available.121
11821 C.F.R. x 330.10(a)(1) (1999). The FDA dened safety as \a low incidence of adverse reactions or signicant side eects
under adequate directions for use and warnings against unsafe use as well as low potential for harm which may result from abuse
under conditions of widespread availability. Proof of safety shall consist of adequate tests by methods reasonably applicable
to show the drug is safe under the prescribed, recommended, or suggested conditions of use. This proof shall included results
of signicant human experience during marketing." 21 C.F.R. x 331.10(a)(4)(i) (1999). \Eectiveness means a reasonable
expectation that, in a signicant proportion of the target population, the pharmacological eect of the drug, when used under
adequate directions for use and warnings against unsafe use, will provide clinically signicant relief of the type claimed. Proof of
eectiveness shall consist of controlled clinical investigations as dened in s. 314.126(b) of this chapter, unless this requirement
is waived on the basis of a showing that it is not reasonably applicable to the drug or essential to the validity of the investigation
and that an alternative method of investigation is adequate to substantiate eectiveness. Investigations may be corroborated by
partially controlled or uncontrolled studies, documented clinical studies by qualied experts, and reports of signicant human
experience marketing." 21 C.F.R. x 331.10(a)(4)(ii) (1999).
11921 C.F.R. x 331.10(a)(4) (1999).
121See id.
233.
Advantages of Treating Homeopathic Drugs as Conventional Drugs
(a) Safety
Although the small amounts of active ingredients used in homeopathic drugs suggest that most homeopathic
drugs are in fact safe, some can be dangerous. First, some homeopathic drugs have been found to contain
substances that are harmful. For example, some homeopathic asthma treatments have been found to contain
articial steroids.122 Second, some homeopathic drugs are not substantially diluted and hence can have toxic
eects. Four doses of homeopathic drugs containing mercury at a dilution of 4X will result in a toxic dose;
a single dose of cadmium 6X is unsafe, and a 6X \dose of Aristolochia contains signicant amounts of this
cancer-causing herb."123 Although the toxic substances are supposed to be in high dilution, studies have
found that some products have \notable quantities" of toxins; in one case two of six homeopathic drugs
received by mail order contained notable quantities of arsenic.124
Another safety concern associated with the use of homeopathic drugs is the lack of sucient regulations over
the practice of homeopathy. As mentioned above, there has been a dramatic increase of consumers seeking
homeopathic treatments. With this demand, there has also been an increase in the supply of homeopathic
drugs. As a result of this growing demand, there is a concern that not all homeopathic practitioners will be
adequately trained to properly apply homeopathic treatments. The FDA should be concerned about these
often unlicensed and untrained practitioners attempting to treat not only minor but also serious ailments
122See National Council Against Health Fraud, supra note 99; Wagner, supra note 23, at 9.
123See Wagner, supra note 23, at 9.
124National Council Against Health Fraud, supra note 99.
24such as AIDS and cancer with homeopathic treatments.125 The problems associated with unlicensed and
untrained practitioners only exacerbates the risks associated with homeopathic drugs because of the concern
that even prescription homeopathic drugs will be misused and increase the risk that they are consumed in
potentially toxic quantities.
By requiring that homeopathic drugs be tested for their safety in varying dosages, consumers can use and
physicians can prescribe homeopathic drugs knowing that they are not at risk of harmful side-eects. Pre-
market approval and the OTC Review should be able to adequately remove unsafe homeopathic drugs from
the market.
(b) Ecacy
Currently, in the case of most homeopathic drugs, there is no evidence that they are in fact eective.126 In
absence of evidence that homeopathic drugs do in fact treat the ailments that they claim they can and do
treat eectively, there is no proof that patients who seek homeopathic drugs are actually being treated. If
in fact patients who use homeopathic drugs are not being adequately treated, these patients are delaying
treatment that could be eective.127 President Taft expressed this same view in an address to Congress in
support requiring proof of ecacy of drugs: \There are none so credulous as suerers from disease. The
need is urgent for legislation which will prevent the raising of false hopes of speedy cures of serious ailments
by misstatements of fact as to worthless mixtures on which the sick will rely while their diseases progress
unchecked."128 Although use of homeopathic drugs to treat the common cold and other self-limiting diseases
125See Homeopathy and `Homeopathy', supra note 11, at 2.
126See supra Part II.
127See Wagner, supra note 23, at 9.
128Kar-ru Chemical Co. v. United States, 264 F. 921 (9th Cir. 1920) (quoting 47 Cong. Rec. pt. 3, 2379 (statement of
President Taft)).
25might not have large ramications, some patients seek homeopathic treatment for serious life-threatening
diseases such as AIDS and cancer. If the homeopathic drugs for these diseases are not eective, then these
patients are delaying treatment that could, in eect, save their lives.
Pre-market approval of homeopathic drugs and the OTC Review would ensure that all homeopathic drugs
on the market are eective. The drugs would be accompanied by studies that indicate the degree of their
eectiveness. Both consumers and physicians will greatly benet from the availability of this data when
deciding whether to use homeopathic drugs.
(c) Non-homeopathic Drugs
Because drug manufacturers are not required to seek pre-market approval for homeopathic drugs, there is
the risk that manufacturers will attempt to side-step the regulations of conventional drugs by marketing non-
homeopathic drugs as homeopathic drugs.129 For example, just recently CigArrest marketed their nicotine
tablets and gum as homeopathic drugs. As homeopathic drugs, CigArrest was not required to seek pre-market
approval for these new drugs, resulting in no testing for their safety and eectiveness. However, neither the
active ingredients in nor method of intake of CigArrest products correlate to homeopathic practices; yet,
they are marketed as homeopathic drugs. Because of this loophole, CigArrest has been marketing this
conventional drug despite the fact that its active ingredient has been found ineective previously. As argued
in a petition by SmithKline Beecham, a manufacturer of a competing drug:
CigArrest is a prime example of a \homeopathic" product that undermines anti-smoking
eorts. It does not appear to be a true \homeopathic" remedy; it is improperly labeled
and promoted; it contains an active ingredient specically prohibited several years ago by
FDA from further marketing for smoking-cessation claims; it diverts smokers seeking help
from proven eective remedies.130
The FDA reviewed lobelia-containing smoking-cessation products, of which CigArrest is one, in its OTC
129National Council Against Health Fraud, supra note 99.
26review process and found that these were not eective.131 Despite this nding, CigArrest continues to
market this product as a homeopathic drug that is not subject to OTC review.
By requiring that homeopathic drugs be subject to the same pre-market approval or OTC Review process
as conventional drugs, this loophole for conventional drugs would be eectively closed. This would have two
benecial eects. First, by requiring pre-market approval for conventional and homeopathic drugs, the FDA
can ensure that all conventional drugs are in fact proven to be both safe and eective. Even if homeopathic
drugs are considered generally safe, the fact that conventional drugs can pass as homeopathic drugs raises
the risk that unsafe or ineective conventional drugs will be marketed as homeopathic drugs in an attempt
to escape pre-market approval. Closing this loophole ensures the safety and eectiveness of all drugs.
Second, requiring that homeopathic and conventional drugs go through the same approval process will
decrease the unfair competition between the two markets. With the current dichotomy between the treatment
of homeopathic and conventional drugs, the market encourages manufacturers to market their drugs as
homeopathic drugs in order to avoid the costs associated with, if not the preclusive eects of, the pre-market
approval process. As a result, drugs that should not be considered homeopathic are being marketed as such.
(d) Insurance Coverage
Another often overlooked concern regarding the lack of proof of safety and eectiveness of homeopathic
drugs is the possibility that with increasing use of alternative remedies, health insurers will cover these
alternative remedies under their policies. For example, managed care is \increasing[ly] willing[] to cover
complementary health care practices."132 Although homeopathic treatments are not (or because they are
131See id. at 15.
132Kathleen Boozang, Western Medicine Opens the Door to Alternative Medicine, 24 Am. J.L. & Med. 185, 187.
27not) proven safe and eective, they are often cheaper than conventional treatments. As a result, there is an
economic incentive for health insurers including Medicare and Medicaid to include alternative remedies and
treatments under their coverage. This consequence has serious eects on the idea of consumer choice. It is
reasonable to argue that, as long as a consumer consents to using alternative treatments she should not be
restricted from doing so by the government. However, it would be unreasonable to require taxpayers, who
might think that alternative remedies are at the same level as quackery, to compensate this person for her
desire to use methods that are not proven to be safe and eective. If homeopathic drugs were to be covered
under government insurance programs such as Medicare and Medicaid, then many taxpayers will be forced
to expend money to support a theory of medicine that they are fundamentally opposed to because it has
not withstood rigorous scientic testing.
Despite these concerns, presently, there are only low rates of insurance coverage for alternative treatments.
Alternative treatments are rarely included in insurance benets, and even when they are covered they are
usually associated with high deductibles or subject to limitations.133 However, an increase in insurance
coverage will most likely be associated with the growing use and acceptance of alternative treatments.
4.
Disadvantages of Treating Homeopathic Drugs as Conventional Drugs
(a) Paradigm Shifting
Requiring homeopathic drugs to seek pre-market approval or submit to the OTC Review is counter to the
very essence of homeopathy because it forces scientic regulations upon an industry that follows a dierent
133See Trends in Alternative Medicine, supra note 6, at 1574.
28paradigm or philosophy of thinking.134 The existing regulations on medical practice in the United States
strongly favor allopathic medicine over alternative forms of medicine. Michael H. Cohen explains:
[T]he existing regulatory environment favors a health care system dominated by orthodox
medicine, based on technological approaches to disease and healing, and modeled on the
assumption that patients lack the requisite sophistication to choose who may minister to
the diseased body. This regulatory approach is not well suited to a health care system in
which [alternative practitioners] and the patient share responsibility for the task of healing,
in which patients value freedom of access to treatment, and in which patient autonomy
supersedes paternalistic approaches to well-being.135
Consequently, the current regulatory scheme results in a system in which allopathic practitioners are painted
as \real" physicians whereas those that practice alternative medicine, including homeopathy, are seen as not
practicing medicine at all or as practicing \quackery."136
The current paradigm focuses on the need to have scientic verication of medical procedures and medica-
tions. This focus is derived from the reliance of conventional medicine on \Cartesian dualism": the notion
that the mind is separate from the body. Hence, under the paradigm of conventional medicine, treatment
of disease is seen as treatment of the body alone|not the patient as a combined unit of body and mind.137
However, alternative medicine, including homeopathy, focuses not only on the body, but also on the patient
as a whole|the mind and the body are treated as a single entity. This approach can be seen in homeopa-
thy's approach to providing a single dosage of a homeopathic drug to treat an individual rather than merely
treating the individual symptoms of a patient separately.
Currently, however, a \paradigm shift" has begun to appear. A paradigm is dened as \a shared set of as-
sumptions about the world, by which individuals dene the parameters of their reality and their investigation
of this reality."138 Because following the current paradigm results in acceptance \within the community, since
134But see Linde, supra note 43, at 840 (\Deciding to conduct research on homeopathy recognises [sic] that this approach is
a relevant social and medical phenomenon.").
136See Wayne B. Jonas, Alternative Medicine|Learning from the Past, Examining the Present, Advancing the Future, 280
JAMA 1616, 1616 (1998).
137See Cohen, supra note 37, at 87.
138Id. at 85.
29they are committed to the consensus reality," a shift in paradigms (or the emergence of a new paradigm)
\generally occurs by revolution rather than by accretion."139 Paradigm shifts consist, generally, of con-
sciousness of the new paradigm, alterations of the old paradigm, and resistance.140 With the growth of
both alternative medicine practitioners as well as consumer demand for alternative treatments, it seems as
if we are amidst a paradigm shift (at least from the perspective of the patient): \It appears that comple-
mentary and alternative medicine has again `come of age' in the United States."141 Furthermore, many
states, including Washington, already are dening homeopathy and some states are including homeopathy
under their understanding of \health care professional."142 Furthermore, Nevada and Arizona each have a
distinct homeopathic licensing board.143 These state eorts suggest that many states are shifting from the
conventional notion of medicine to a view of medicine that includes alternative medicine. This paradigm
shift is altering the concept of medicine from that of being purely scientic, orthodox medicine, to that of
alternative medicine, which sees treatment in a more holistic fashion.144
Recognition of the fact that homeopathy exists in an entirely dierent paradigm than conventional medicine
raises the problem that subjecting homeopathic drugs to the same testing procedures as conventional
medicine is an attempt to t a regulatory scheme where it is inapplicable. Homeopathy relies on no-
tions such as treating the patient as a whole, providing individualized treatments, and relying on the belief
that the spirit of the active ingredient remains in the drug despite high-dilutions. These notions are in-
herently inconsistent with the conventional methods of scientic clinical studies because the very idea that
homeopathic drugs are meant to have a consistent eect on dierent individuals is contrary to the practice
139Id.
140Id.
141Jonas, supra note 136, at 1616. At least one commentator believes that the paradigm shift is well on its way: \The
popularity of [physicians in natural medicine has] signal[ed] the beginning of the end of orthodox medicine's dominance of
health care in the United States." Boozang, supra note 132, at 187. Although this is probably an exaggerated viewpoint, it
reveals at least the nature of the shift that is occurring, although at a slower rate.
142Cohen, supra note 135, at 92, 95.
143See id.
144See Cohen, supra note 37, at 79.
30of homeopathy.145 It would be very dicult to create clinical trials for many homeopathic drugs because
they are specic to the individual patient|any reproduction of the results would be very dicult if not
impossible. From the perspective of homeopathy, the experience of the individual is more important than
experimental results.146 Furthermore, although homeopathy might appear to be consistent with allopathic
medicine in some respects, homeopathy implicitly rejects allopathic medications, arguing that they merely
mask a patient's symptoms, leaving the disease untreated.147
[A]lternative medicine comprises a large and heterogeneous group of treatments, many of
which are procedures that are not readily testable under blinded conditions and for which
the choice of appropriate control conditions is by no means straightforward. Furthermore,
alternative medicine therapies may also possess a theoretical basis, may stem from a cultural
tradition that is seemingly antithetical to a quantitative, biomedical framework, or may
possess little foundational research on which to base a controlled evaluation.148
Thus, the FDA must make a dicult and crucial choice regarding with which paradigm it wants to judge
homeopathic drugs.
Adoption of the paradigm of conventional medicine has two major disadvantages: it entrenches the views
of conventional medicine and it undermines consumer choice.149 Although many might think that reliance
on scientic evidence and conventional medicine are crucial aspects of health care, this very notion is en-
trenched in the paradigm of orthodox medicine. Use of this scientic paradigm serves to undermine both the
availability and development of potentially eective alternative approaches to medicine.150 Michael Cohen
explains the negative eects that orthodox medicine has had on the development of alternative remedies:
145Cf. Practice and Policy Guidelines Panel, National Institutes of Health Oce of Alternative Medicine, Clinical Practice
Guidelines in Complementary and Alternative Medicine, 6 Archives of Family Med. 149,152 (\The individualization of
treatment that characterizes [complementary and alternative medicine] is antithetical to the goals of practice guidelines, which
tend to seek reductions in practice variation. This tension between individualization and uniformity represents another obstacle
to practice guideline development....").
146See Wagner, supra note 23, at 8 (noting the view of Dana Ullman, \a prominent spokesperson for American homeopathy").
147See Cohen, supra note 135, at 111.
149See Cohen, supra note 37, at 80.
150See Cohen, supra note 135, at 86.
31Many patients who might benet from alternative healing modalities nd themselves unable
to aord, or even obtain, such treatments. Defenders of orthodoxy urge further randomized,
double-blind studies proving ecacy. Yet, even as studies emerge, medical boards, insurers
and lawmakers must move beyond a paradigm which, for historical and economic reasons,
has dominated American health care since the late nineteenth century. The paradigm belit-
tles or dismisses healing modalities outside medical orthodoxy, and reects an overreliance
on surgery and medication to heal disease.151
As another example of the clash between the two paradigms, medical boards, which have a great deal of
authority over the licensing of physicians, have historically rebelled against physicians who practice homeo-
pathic medicines.152 As long as the current orthodox paradigm remains dominant, it will continue to hold
back alternative remedies. Subjecting homeopathic drugs to the same requirements as conventional drugs
would probably remove most homeopathic drugs from the market because of their inability to meet the
rigorous demands of science153|not necessarily because homeopathic drugs are ineective, but rather sim-
ply because homeopathic drugs are not suited to survive the testing scheme that has been established by
orthodox medicine itself.154
Second, the denial of entry of homeopathic drugs into the market undermines consumer choice and freedom.
As long as the consumer is informed as to the present state of eectiveness and safety of any given drug,
it seems unreasonable to allow the FDA to deny the consumer access to this drug simply because the FDA
has determined that the drug is not safe and eective (as dened by orthodox medicine).155 There is a
strong demand for alternative treatments presently, and for the government to deny access to alternative
152See id. at 111-14. Cohen refers to two independent cases, In re Guess, 393 S.E.2d 833 (N.C. 1990), cert. denied, 498 U.S.
1047 (1991), and Metzler v. New York State Board for Professional Medical Conduct, 610 N.Y.S.2d 334 (App. Div. 1994),
appeal dismissed, 616 N.Y.S.2d 479 (N.Y. 1994), in which the courts upheld disciplinary actions against homeopathic physicians.
See id. The medical board \appears to have singled out [the physicians] for termination of licensure merely because of [their]
homeopathic leanings { just as allopathic physicians had singled out homeopaths for extinction some ninety years earlier." Id.
at 113; see supra Part I.
153Even the less rigorous standards of the OTC Review would require scientic evidence that shows the ecacy of homeopathic
drugs. This standard would be dicult to meet because of the large absence of clinical studies of homeopathic drugs.
154But see Fundamental Research in Ultra High Dilution and Homeopathy, supra note 45, at 6-7 (suggesting that
homeopathic drugs can be submitted to conventional research strategies).
155However, consumer choice only extends as far as adults and not children|children are not able to properly choose among
treatments. See Stehlin, supra note 3.
32treatments is governmental paternalism at its worst. Because consumers are increasingly seeking holistic
approaches to medicine in which the physician sees the patient as a person and not merely as a disease to
be treated, consideration of how to treat homeopathic drugs should not be made in a vacuum, independent
of the consumer's interests.156 Without proof that the consumer is actually at risk of harming herself, there
seems to be little reason for the government to deny access to the consumer as long as her consent is informed.
Unfortunately, the \`softness' of alternative medicine, which many regard as its main strength, is from the
standpoint of conventional regulation, its chief weakness. It cannot stand up to standard modes of scientic
inquiry|randomized clinical trials, double-blind studies, and the like|because, in important dimensions, it
is more a philosophy than a protocol."157 Those who advocate that homeopathic drugs should show safety
and eectiveness would argue that it is undeniable that consumers rely on the safety and eectiveness of
homeopathic drugs; to this extent such drugs should be required to show that they can in fact survive this
hurdle. To require otherwise would only serve to undermine not only consumer safety158 but also consumer
choice: without proof of safety and eectiveness, a consumer's choice to use homeopathic medicine is an
entirely uninformed choice. Thus, the argument goes, the best means of preserving consumer choice is by
providing consumers with choices that are actually proven to do what they claim to be able to do. \It is
insucient to say that, because randomized clinical trials are inappropriate for unconventional treatments,
no testing at all need occur before a new therapy becomes the standard of care. If testing protocols are
necessary, so be it."159
156See Mike Mitka, FDA Never Promised an Herb Garden|But Sellers and Buyers Eager to See One Grow, 280 JAMA
1554, 1554 (1998).
157Boozang, supra note 141, at 207-08.
158See supra Part IV.A.3(a).
159Boozang, supra note 141, at 208. See also Phil B. Fontanarosa & George D. Lundberg, Alternative Medicine Meets Science,
280 JAMA 1618, 1618 (1998) (\For virtually all medical therapies and interventions, whether conventional or alternative,
determination of eectiveness and recommendations for clinical application should be based on the strength of the scientic
evdience using explicit criteria for grading the quality of evidence and ratings for technology assessment....").
33Although states have the power to regulate the medical eld (e.g., through overseeing the licensing of
practitioners),160 the FDA should be aware of this emerging paradigm shift and the eects that its policy
could have on the current dichotomy between scientic medicine and alternative medicine when formulating
changes in its approach to homeopathic drugs.
(b) Monetary Consequences
The most striking drawback of requiring homeopathic drugs to show safety and eectiveness is the large cost
that it will have on the industry. The cost of the entire testing process as well as the NDA is placed entirely
on the manufacturer. Furthermore, not only is the manufacturer required to pay for the tests, but the FDA
also requires that the company pay user fees to reimburse the FDA for reviewing the NDA.161
The estimated cost to the manufacturer to test each drug for pre-market approval is high and growing.
The average cost of both researching and developing a new drug and ling a successful NDA is over $230
million.162 Furthermore, the estimated time to go through the entire drug approval process has grown from
160See Cohen, supra note 135, at 87. Of note, some of the deleterious eects of alternative medicine could be alleviated
through a more stringent regulation of practicing homeopaths. For example, several states currently regulate the practice of
homeopathic medicine through a licensing scheme. See id. at 92.
161New Drug and Antibiotic Application Review; Proposed User Charge, 50 Fed. Reg. 31,726 (1985) (to be codied at 21
C.F.R. pt. 314) (proposed Aug. 6, 1985).
162See Walsh & Pyrich, supra note 107, at 931 (deriving this amount from a report from the Center for the Study of Drug
Development at Tufts University). Another study presents an even higher estimate:
Pharmaceutical drug development costs have risen steadily over the last forty years. Data from various sources have estimated
that the costs of discovering and developing a new drug have risen from about $50,000,000 in the 1970s, through $200,000,000
in the 1980s, and to $400-$500,000,000 today. The time required to develop a new drug also has increased, moving from about
one year in the 1950s to over ten years today.
John F. Niblack, Why are Drug Development Programs Growing in Size and Cost? A View From Industry, 52 Food & Drug
L.J. 151, 151 (1997) (\Marketplace factors of the 1990s are forcing developers of new drugs to increase development program
content while they simultaneously strive to compress program length. Concurrently, regulatory and scientic requirements
regarding the quality, quantity, and completeness of data are on the rise. This combination of factors is inating new drug
development costs markedly, and there are no signs of relief in sight.").
34two to three years in 1962 to as long as twelve years.163 At these costs of both time and money to the manu-
facturer, the requirement that homeopathic drugs be subject to pre-market approval would almost certainly
preclude their sale on the market. This is particularly the case because, although homeopathic drugs do in
fact have a growing market, the market for them does not compare to that of allopathic drugs.
To put the costs in perspective, it is appropriate to consider the economic burdens of subjecting homeopathic
drugs to the same restrictions as conventional drugs with respect to tests for merely identity and strength
and restrictions on the use of alcohol in their drugs. The homeopathic industry made this same cost argu-
ment when the FDA proposed that homeopathic drugs be subject to the same restrictions as conventional
drugs.164 The homeopathic industry argued that these requirements would be far too costly because of the
rigid testing requirements that they would require. In particular, with respect to the use of alcohol in liquid
dosages, the comments suggested that this requirement would require an entirely new formulation of their
drugs, which would require new tests for their ecacy. Even this limited amount of testing was argued to
be formidable for the homeopathic drug industry.165 It seems highly likely, as a result, that the requirement
of proving safety and eectiveness of homeopathic drugs would, at least for most manufacturers and most
drugs, preclude them from ever reaching the market.
Furthermore, the homeopathic drug industry is confronted with a unique problem of patenting issues. Un-
like many conventional drugs, the majority of homeopathic drugs are derived from plants, making them
unavailable for patenting.166 \Most plant-derived drugs are categorized as `works of nature' and, as such,
163See Walsh & Pyrich, supra note 107, at 934. In 1980, the estimated time for the completion of pre-market approval testing
was found to be between seven and thirteen years. See Process for Approving New Drugs, supra note 112, at 514.
164See Over-the-Counter Drug Products Intended for Oral Ingestion that Contain Alcohol, 60 Fed. Reg. at 13,593.
165Even the OTC Review would be costly for manufacturers of homeopathic drugs to the extent that they would have to
perform clinical studies to show the eectiveness of their drugs. Even though there is a less stringent testing requirement, the
homeopathic drug industry would be starting from scratch in terms of proof of eectiveness, making the costs to the industry
high. It should also be noted that the OTC Drug Review has been an intense, dicult, and complicated regulatory scheme.
See Hutt & Merrill, supra note 112, at 609. It is still ongoing because of the sheer size of the project, and as a result, its
priority within the FDA has fallen. See id. Thus, the costs to the FDA of extending the OTC Review to include homeopathic
drugs should also be considered when evaluating the overall costs of this approach.
16670% of homeopathic drugs are derived from plants. See Bob Leckridge, Homeopathy in Primary Care 15 (1997). The
remaining 30% are prepared from other natural sources such as minerals and animals. See id.
35are not patentable under current law."167 Under the current regulatory system, the eect of this is not felt
because of the low cost of entering the market. However, requiring homeopathic drugs to submit proof of
safety and eectiveness would create large costs to those manufacturers that choose to meet this burden.
Furthermore, because these manufacturers could not patent their newly tested drug, there is little incentive
for them to test them in the rst place. With patentable drugs, \the U.S. market share for a drug declines
immediately and precipitously upon expiration of its patent protection";168 it is reasonable to assume that
absent a patent at all, homeopathic drug manufacturers would have no economic incentive to engage in the
large costs of obtaining market approval.169 The system would encourage manufacturers to hold out testing
their own drugs until other manufacturers have incurred the costs of testing their own drugs. As a result of
this holdout dilemma, there is the likely possibility that manufacturers will not seek approval of homeopathic
drugs at all because of their lack of protability.
(c)
Political Ramications
As discussed above, requiring proof of safety and eectiveness of all homeopathic drugs would probably
remove the availability of these alternative remedies from the market. The widespread decline in the avail-
ability of an increasingly popular alternative to orthodox medicine will probably carry with it large political
ramications for the FDA. As with the FDA's once stringent regulations over dietary supplements,170 the
FDA will probably meet a great deal of political opposition with the adoption of such strict regulations
of homeopathic drugs. The public largely sees the FDA's role as regulating drugs for the benet of the
167Cataxinos, supra note 8, at 574 (citation omitted).
168Niblack, supra note 162, at 153.
169See Daniel P. Eskinazi, Factors that Shape Alternative Medicine, 280 JAMA 1621, 1622 (1998).
170See infra Part IV.B.
36public. However, by foreclosing an option that many people have sought out and are increasingly seeking
out, the FDA could be perceived as over-stepping its regulatory function. In the absence of any evidence
that homeopathic drugs are in fact unsafe, the FDA will could be seen as undermining consumer choice and
freedom. The FDA was forced to capitulate with respect to dietary supplements, and will probably be forced
to as well with respect to homeopathic drugs.
5. Conclusions on Treating Homeopathic Drugs as Conventional Drugs
Requiring proof of safety and eectiveness of homeopathic drugs would both have preclusive costs on the
industry and unreasonably submit homeopathic drugs to tests that they are highly unlikely to survive. As
a result, this piece suggests other alternatives that the FDA could utilize which would accomplish many of
the same benets of proving safety and eectiveness while not precluding homeopathic drugs from entering
the market and thus undermining consumer choice.
B.
Treating Homeopathic Remedies as Dietary Supplements
1. The Treatment of Dietary Supplements
One alternative would be to treat homeopathic drugs not as drugs at all, but rather dene them to be dietary
supplements. It should be noted, however, that this alternative would require a statutory amendment be-
cause, currently, a homeopathic remedy is dened as a \drug" in the Federal Food, Drug, and Cosmetic Act
37of 1938|this was left unchanged in the 1962 amendments to the Act.171 However, assuming that such an
amendment could be achieved, this alternative would allow homeopathic remedies to remain on the market
without requiring them to go through a rigorous testing process.
In 1994, Congress passed the Dietary Supplement Health and Education Act (DSHEA). This amendment
to the Federal Food, Drug, and Cosmetic Act of 1938 was passed largely in response to political lobbying in
favor of deregulating dietary supplements.172 \A national `Blackout Day' was engineered by thousands of
retailers of dietary supplements[, and a] lobbying day on Capital Hill was staged by the dietary supplement
manufacturers."173
DSHEA classies dietary supplements under a new and distinct category of food. Several changes from the
1938 Act's approach to dietary supplements resulted. First, manufacturers of dietary supplements no longer
have to prove that their products are safe prior to their marketing, as would be required had they been
considered as food additives. Second, the amendment requires that FDA show that the dietary supplement
has been adulterated under the 1938 Act|FDA bears the burden of proof.174 Third, dietary supplements
are permitted to make claims that the supplement positively aects the human body's structure and/or
function (structure/function claims) and certain authorized
\statements that pertain to a disease or health-related condition" (health claims), which previously could
have caused dietary supplements to be regulated as drugs.175 Specically, DSHEA \allows dietary supple-
ment labeling to bear a statement that `describes the role of a nutrient or dietary ingredient intended to aect
the structure or function in humans' or that `characterizes the documented mechanism by which a nutrient
or dietary ingredient acts to maintain such structure or function....' Statements permitted under...the act
171See 21 U.S.C. x 321(g)(1) (1998).
172See Peter A. Vignuolo, Note, The Herbal Street Drug Crisis: An Examination of the Dietary Supplement Health and
Education Act of 1994, 21 Seton Hall Legis. J. 200, 202-03 (1997).
173Id. at 216-17.
174See id. at 223-24.
175Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or Function
of the Body, 63 Fed. Reg. 23,624, 23,624 (1998) (to be codied at 21 C.F.R. pt. 101) (proposed April 29, 1998).
38`may not claim to diagnose, mitigate, treat, cure, or prevent a specic disease or class of diseases,' except
that such statements may claim a benet related to a classical nutrient decient disease, provided that they
also disclose the prevalence of the disease in the United States."176 \[A] dietary supplement manufacturer
who wishes to make a permitted structure/function statement under...the act must have substantiation
that the statement is truthful and not misleading, and must include in the state the following disclaimer:
`This statement has not been evaluated by the Food and Drug Administration. This product is not intended
to diagnose, treat, cure, or prevent any disease."'177 The FDA also permits dietary supplements to make
\certain statements that pertain to a disease or health-related condition [provided that the health claim
is] authorized by FDA before they may be used on the label or in the labeling of a food or dietary sup-
plement."178 Before the passage of DSHEA, both structure/function and health claims would classify the
product as a drug under the Federal Food, Drug, and Cosmetic Act.
2. Advantages of Treating Homeopathic Remedies as Dietary Supplements
The main advantage of classifying homeopathic remedies in the same category as dietary supplements is
that homeopathic remedies, which are not tested for safety and eectiveness, will no longer be marketed
as drugs at all. Under this scheme, homeopathic remedies will not bear the imprimatur of conventional
medicine. As a result, consumers choosing to take homeopathic remedies will be on notice that the remedy
that they are consuming is not tested for safety and eectiveness and is not generally recognized by the
176Id.; see 21 U.S.C. x 341(r)(6) (1998). If a dietary supplement is intended to be used to \diagnose, cure, mitigate, treat, or
prevent a disease, then it can be treated as a drug. See id.
177Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or Function
of the Body, 63 Fed. Reg. at 23,624; see 21 U.S.C. x 341(r)(6) (1998).
178Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or Function
of the Body, 63 Fed. Reg. at 23,624; see 21 U.S.C. x 341(r)(1)(B) (1998).
39conventional scientic community as safe and eective. Furthermore, by limiting the claims of homeopathic
remedies to structure/function and approved health claims, rather than disease claims, the risk of consumer
deception will be reduced.179 Consequently, the harm that results from the delay of treating diseases caused
by ineective homeopathic remedies will likely be reduced as well. Although this approach does not ensure
the safety and eectiveness of homeopathic remedies, it is no worse than the status quo with respect to the
FDA's stance (or lack thereof) on showing the safety and eectiveness of homeopathic remedies.180
Additionally, this approach would not subject homeopathic remedies to regulations that they are incapable
by their very nature of surviving. By not subjecting homeopathic remedies to the standard of orthodox
methodology, the alternative paradigm to conventional medicine will survive. Although it could be argued
that, perhaps even more so than requiring pre-market approval of homeopathic remedies, the classication of
homeopathic remedies as dietary supplements would clearly place homeopathic remedies outside of the eld
of medicine. As such, homeopathic remedies would be excluded from valid medicine, not on any meritorious
ground, but solely because homeopathic remedies are seen as alternative remedies. As the argument goes,
such a classication of homeopathic medicine would most likely further undermine its credibility without
ever having the opportunity to prove its eectiveness. However, this argument is awed because rather
than requiring that homeopathic remedies be tested for safety and eectiveness, classifying them as dietary
supplements would not require that they be held to the same standard (which is today purely an orthodox
scientic one) as conventional drugs. As such, this approach would not force homeopathic remedies, which
are not conducive by their very nature to the rigorous testing that is required of pre-market approval, to show
their eectiveness through clinical trials. This would ultimately preserve the alternative medicine paradigm.
179However, it should be noted that there is the inherent diculty in distinguishing between disease claims and struc-
ture/function claims. As a result, it is unclear exactly how much of a benecial eect limiting the claims of homeopathic
remedies to structure/function claims will in fact have. But see Regulations on Statements Made for Dietary Supplements
Concerning the Eect of the Product on the Structure or Function of the Body, 63 Fed. Reg. at 23,624 (attempting to clarify
the distinction between disease claims and structure/function claims).
180One could also require of homeopathic remedies the same labeling requirements that are currently specied in the Com-
pliance Policy Guide even once they are classied as dietary supplements. This would provide almost the same benets of the
FDA's current stance on homeopathic remedies.
403. Disadvantages of Treating Homeopathic Remedies as Dietary Supplements
Despite the fact that treating homeopathic remedies as dietary supplements might appear to allow them to
remain on the market, there are several impediments in the FDA's treatment of dietary supplements that
will complicate this alternative.
First, it is unclear how homeopathic remedies would even be able to satisfy the requirements necessary to
make structure/function claims. The FDA requires that all structure/function claims \must have substan-
tiation that the statement is truthful and not misleading...."181 This requirement alone would be dicult
for many homeopathic remedies to survive because it would require some degree of proof of ecacy of
the remedy. The FDA's regulation of dietary supplement claims is far less rigorous than its regulation of
drug claims. Of the approximate 2,300 structure/function notications that the FDA has received since
the passage of DSHEA, it has found only about 150 of them to be problematic.182 However, it seems that
homeopathic remedy manufacturers would still confront diculties in placing structure/function claims on
their labels because they would be unable to substantiate their claims. Furthermore, it is even more unlikely
that homeopathic remedies would be able to survive the FDA's requirements to make health claims. Under
FDA's regulations, health claims must be accompanied by a summary that establishes that \based on the
totality of publicly available scientic evidence (including evidence from well-designed studies conducted in
a manner which is consistent with generally recognized scientic procedures and principles), that there is
signicant scientic agreement among experts qualied by scientic training and experience to evaluate such
claims, that the claim is supported by such evidence."183 Because homeopathic remedies would rarely be
181Regulations on Statements Made for Dietary Supplements Concerning the Eect of the Product on the Structure or Function
of the Body, 63 Fed. Reg. at 23,624.
182See Mitka, supra note 156, at 1555.
18321 C.F.R. x 101.14, 101.70 (1999). Even if the FDA allowed dietary supplements to make general health claims based on
authoritative statements, see 21 U.S.C. x 343(r)(2)(G) (1998), as recently proposed by the FDA, see Food Labeling: Use on
Dietary Supplements of Health Claims Based on Authoritative Statements, 64 Fed. Reg. 3250 (1999) (to be codied at 21
41able to produce this level of scientic certainty, they would probably be limited to making structure/function
claims.
Second, it would be very dicult to limit the claims of homeopathic remedies to those of structure/function
claims or health claims as opposed to claims to treat disease. Even if homeopathic remedies limited their
labeling to claims regarding treatment of mere symptoms, many symptoms are clearly associated with
diseases. As a result, few homeopathic remedies would be able to make the same claims that they do under
the current regulatory system. Thus, although homeopathic remedies could still be marketed as dietary
supplements, they would bear inadequate labeling for indications of use and directions for use because they
would be unable to make claims as their eects on the body. This result would leave the consumer without
any information regarding how and when to use homeopathic remedies, which would most likely lead to the
misuse of these remedies.
Third, this reclassication is potentially dangerous because it would simply reduce the current regulations
over homeopathic remedies. As dietary supplements, homeopathic remedies would not be subject to any
regulations other than the labeling requirements associated with dietary supplements and the aforementioned
restrictions. This solution would make no attempt to determine the safety and ecacy of such remedies,
merely leaving potentially unsafe and ineective remedies on the market (without adequate labeling). This
problem is exacerbated by the existence of prescription-only homeopathic drugs. It is unclear how these could
be treated as dietary supplements because they require the supervision of a physician to oversee their safe
and proper use and application. The FDA would be forced to regulate these drugs independently in order
to ensure that potentially unsafe products are not readily available on the market to the unwary consumer.
C.F.R. pt. 101) (proposed January 21, 1999), it is unlikely that many homeopathic manufacturers would be able to rely on this
mechanism because of the lack of current research on homeopathic drugs.
424. Conclusions on Treating Homeopathic Remedies as Dietary Supplements
Although treating homeopathic remedies as dietary supplements would ensure that they would remain
available to consumers to use if they so choose, it would result in the deregulation of the industry. This
approach would ensure that homeopathic remedies are no longer treated as drugs and, as a result, misrep-
resented to consumers as safe and eective. However, because homeopathic remedies would be unable to
substantiate their claims, they would be forced to market without indications for use, which would almost
inevitably result in their misuse. Thus, this approach would only result in presenting less information and
protection to consumers than the FDA's current regulations.
C. An Intermediate Solution|Creating a Regulatory System Specic to Homeopathic
Drugs
Because of the diculties associated with requiring homeopathic drugs to prove safety and eectiveness as
well as the diculties with decreasing the FDA's homeopathic drug regulations, an intermediate solution
seems most appropriate. Because of the unique nature of homeopathic remedies, the FDA should design a
regulatory structure that best meets the needs of patients and consumers while not undermining the stability
of the entire homeopathic drug industry.184
184This intermediate design is similar to the approach that the European Community is attempting to design. Its stated
goals are \to ensure the accessibility of homeopathic medicinal products, to guarantee the reliability and safety of these
products, to guarantee information for users of homeopathic medicinal products, and to harmonize partially the rules regarding
the production and monitoring of these products." Report on the Commission Report to the European Parliament and the
431. The Proposal
Rather than requiring homeopathic drugs to be proven both safe and eective under the standards of
conventional medicine, the FDA could monitor homeopathic drugs and require that they be proven to
be safe and eective, where eectiveness is viewed from the standpoint of homeopathy.185 This scheme could
be designed similarly to the process of OTC Review, in which the FDA creates monographs for particular
active ingredients, except for three major dierences.
First, it would include all homeopathic drugs, prescription and non-prescription, rather than being restricted
to OTC drugs. Although most homeopathic drugs are sold OTC,186 it is important to include prescription
drugs under this review because prescription homeopathic drugs are most likely to contain doses of active
ingredients that could be toxic.187 Furthermore, it is important to ensure that as many homeopathic drugs
as possible are included under review. For those homeopathic drugs that claim to fall under the grandfather
clauses of the 1938 Act and the 1962 amendments, the FDA could take eorts to include as many as possible
under this new scheme. Empirically, as the FDA successfully did with the OTC Review, the FDA could
subject all OTC homeopathic drugs to this new requirement under the same rationale that the grandfather
clauses do not apply to misbranding:
Council on the Application of Directives 92/73/EEC and 982/74/EEC on Homeopathic Medicinal Products, Committee on the
Environment, Public Health and Consumer Protection, Oct. 28 1998, at 10. Of note, the EC is attempting to take a unique
approach to homeopathic products in order to ensure the free marketing of homeopathic drugs. See id.
185Because there is little dierence between the allopathic and homeopathic understandings of safety it seems reasonable to
subject homeopathic drugs to the conventional standard of safety.
186See National Center for Homeopathy, supra note 110, at 4.
187See supra Part III.B (noting that drugs with a high degree of toxicity are considered prescription drugs).
44The [OTC] review... is designed to particularize not just the new drug provisions of the
act, but also the misbranding provisions. Accordingly, the grandfather clauses in no way
preclude the agency from reviewing, through a rule making procedure, the thousands of
OTC drugs now on the market that are properly the subject of grandfather protection from
the new drug provisions in order to make certain that they comply with the misbranding
provisions of the act.188
Furthermore, the FDA could attempt to include prescription drugs under this design as well, arguing that
prescription drugs are also misbranded.
Second, a homeopathic drug review would require manufacturers to show that the drug is safe and eective,
where eectiveness is dened from the perspective of homeopathy. The determination of \eectiveness"
could be modeled after the approach taken by the Homeopathic Pharmacopoeia of the United States. This
system both ensures that homeopathic drugs are safe and that they have adequate provings. Provings are
similar to Phase 1 clinical trials of a new drug application:
Homeopathic drug provings on healthy volunteers are carried out according to Hahnemann's
classical directions, and also adhere to the current regulations for conventional clinical trials.
Because homeopathic drug provings are pharmacological studies on healthy volunteers, they
are quite similar to Phase I clinical trials as mentioned in current drug laws (good clinical
practice).189
These provings as well as tests on safety, could be used as the basis for monographs of the active ingredients
of homeopathic drugs, which would ensure that homeopathic drugs are in fact safe and eective under the
standards of homeopathy.
Third, the FDA would make eorts to have the expert panel consist of experts in homeopathy rather than
merely conventional medicine. This would ensure that conventional methodologies are not used to measure
the safety and eectiveness of homeopathic drugs. As a result, those drugs that are safe and eective under
the standards of homeopathy would have approved monographs.
452. Disadvantages of an Intermediate Solution
Clearly, the fact that this approach would allow the marketing of drugs that are not proven eective according
to conventional standards is its largest disadvantage. Requiring that homeopathic drugs have provings is not
comparable to the rigorous testing required of conventional drugs. However, because of the unique nature
of homeopathic drugs, it would be unreasonable to subject them to the testing standards of conventional
medicine. As discussed above, the very nature of homeopathic drugs is contrary to proving their eectiveness
using the conventional testing methods. By requiring that homeopathic drugs show ecacy through the
mechanism of traditional provings, the FDA will ensure that homeopathic drugs are authentic as determined
within the eld of homeopathy rather than requiring them to show their ecacy by the incompatible processes
of orthodox science. As a result, those consumers who choose to practice homeopathy will be guaranteed
that they are buying safe and eective drugs as determined by homeopathic physicians.
3. Advantages of an Intermediate Solution
Allowing homeopathic drugs to submit to an intermediate review rather than to the stringent standards of
conventional medicine would capture many of the advantages while not accruing the large disadvantages of
subjecting them to the standards of conventional medicine.
(a) Safety
46This review system would ensure that those homeopathic drugs that are on the market are in fact safe.
This is important especially for those homeopathic drugs that contain known toxins. Currently, drugs that
contain known toxins at low dilutions are available on a prescription-only basis. For example, although
arsenic at a dilution of 6X is available OTC, 1X arsenic is only available with a prescription.190 However,
there is no requirement from the FDA, currently, that the 1X dilution be shown to be safe.
Furthermore, the public has access (without a prescription) to homeopathic drugs that are at extremely high
dilutions (such as 200X). Although \[t]hese high potency medicine are not dangerous in the traditional sense
of toxicology... [t]hey are... deeper-acting medicines which have the potential to create a healing crisis|
that is, an increase in certain supercial symptoms."191 During these healing crises, patients experience an
increase in their symptoms, which are similar to side eects associated with conventional drugs. Furthermore,
homeopathic drug manufacturers probably do not report these adverse eects to the FDA.192 Because of the
risk that these drugs could in fact harm consumers it is important to guarantee the safety of the patient;
the proposed safety review would ensure this safety.
(b) Non-homeopathic Drugs
Furthermore, by requiring homeopathic drugs to submit to a review that is monitored by homeopathic
specialties, the FDA can weed out those conventional drugs that are falsely identifying themselves as home-
opathic drugs in order to avoid showing both safety and eectiveness under conventional drug standards.
This would protect the consumer from conventional drugs that have not gone through the required testing
and ensure that only truly homeopathic drugs bear that label. This will protect the consumer from consum-
190See Ullman, supra note 5, at 153-54.
191Id. at 157-58.
192National Council Against Health Fraud, supra note 99.
47ing drugs that could very well have harmful side eects that were not detected in the pre-market approval
process.
(c)
Costs
The largest advantage of this approach is that it would allow the homeopathic drug industry to continue
in a safe manner without requiring that it submit to the testing standards of conventional medicine, which
would most likely preclude many, if not most, homeopathic drugs from ever reaching the consumer because
of the high costs associated with such rigorous testing. Unlike more strict alternatives, a requirement to
show that homeopathic drugs are safe and have provings need not be preclusive for the manufacturers. In
fact, many homeopathic drugs already have provided evidence of provings to the HPUS. Furthermore, many
homeopathic drugs can easily be proven to be safe because of their benign active ingredients and others can
be proven safe by virtue of their high dilutions. The requirement to show safety would have its largest eects
on those homeopathic drugs that contain known toxins, but it is these homeopathic drugs that deserve the
highest scrutiny. In addition, unlike the very time consuming and costly nature of the OTC review, which
involved hundreds of thousands of drugs, a homeopathic review would only need to consider about 2,000
monographs193 because of the limited number of active ingredients used in homeopathic drugs. As a result,
a homeopathic review would be less costly for the FDA as well.
(d)
193See Report on the Commission Report to the European Parliament and the Council on the Application of Directives
92/73/EEC and 982/74/EEC on Homeopathic Medicinal Products, supra note 184, at 11.
48Paradigm Shifting and Political Ramications
This approach would also ensure that homeopathic drugs remain available to consumers. The FDA would
not be taking eorts to quash alternative medicine by forcing it to submit to the standards of orthodox
medicine, with which it is in conict. As a result, this intermediate requirement would avoid the large
political ramications associated with undermining the homeopathic drug industry and the resulting negative
eect this would have on consumer choice. This intermediate approach seeks to provide to the consumer
those drugs that are in fact safe and eective according to the industry's standards. Thus, this approach
would regulate homeopathic drugs so that, while it would allow consumers to use ineective drugs according
to conventional medicine standards, it would not allow them to use unsafe and unproven homeopathic drugs.
V. Choosing Among Alternatives
The diculty in choosing among the presented alternatives is understandable because a choice among them
requires a choice as between distinct paradigms. Requiring homeopathic drugs to show safety and eective-
ness as with conventional drugs clearly rejects the paradigm of alternative medicine in favor of an entirely
scientic and orthodox paradigm. Although this approach, which lies at one end of a spectrum of alternative
reforms, has the largest costs on the homeopathic industry, it also ensures to the greatest extent the safety
and eectiveness of homeopathic drugs.
At the other end of the spectrum, simply classifying homeopathic remedies as dietary supplements would
allow the alternative paradigm to thrive by not subjecting these drugs to rigorous scientic testing. The
obvious drawback of this solution is its inability to address at all the safety and eectiveness of these drugs.
49Creating a Homeopathic Drug Review process falls at the middle of this spectrum. A review process would
allow for the testing of homeopathic drugs, which would ensure consumers that these drugs are safe and
eective. Yet, this testing would not undermine the alternative paradigm because it would recognize alter-
nate forms of experimentation that could prove the safety and eectiveness of homeopathic drugs, namely
provings.
The FDA, as a regulatory agency, cannot ignore the risks of public safety despite the consequences that
regulating the eld of homeopathic drugs will have on the industry. Thus, submitting homeopathic drugs to
a review process appears to be both a viable and advantageous approach for the FDA to take with respect
to the growing use and availability of homeopathic drugs. Despite the uncertainty involved with a homeo-
pathic drug review, it is clear that some action by the FDA is appropriate. As Dr. Jonas, the scientist who
conducted successful experiments of homeopathic drugs194 concluded:
Alternative medicine is here to stay. It is no longer an option to ignore it or treat is
as something outside the normal processes of science and medicine. The challenge is
to move forward carefully, using both reason and wisdom, as we attempt to separate
the pearls from the mud.195
194See Linde, supra note 43.
50